<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254759</url>
  </required_header>
  <id_info>
    <org_study_id>WP29393</org_study_id>
    <secondary_id>2014-001850-41</secondary_id>
    <nct_id>NCT02254759</nct_id>
  </id_info>
  <brief_title>A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a non-randomized, open-label, five treatment, fixed sequence cross-over study to
      investigate the effect of RO5186582 treatment on CYP3A activity using midazolam as a probe
      CYP3A substrate, and also to assess the pharmacodynamic measures of brain electrical activity
      and sedation to explore the pharmacodynamic interaction between the gama-amino butyric acid
      (GABA)A negative allosteric modulator RO5186582 and the prototypical GABAA positive
      allosteric modulator midazolam. The anticipated study duration is up to nine weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of Drug (F) for Oral Midazolam</measure>
    <time_frame>Pre-dose [-0.5 hour (h)] and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h post-dose (pd) on Day (D) 2 and 18, and 22 h pd on D3 and 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Plasma Clearence (CL) for IV Midazolam</measure>
    <time_frame>Pre-dose [-10 minutes (min)] and 0.08 (5 min), 0.25 (15 min), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and D17, and 22 h pd on D2 and D18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution at Steady-State (Vss) for IV Midazolam</measure>
    <time_frame>Pre-dose (-10 min) and 0.08 (5 min), 0.25 (15 min), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and D17, and 22 h pd on D2 and D18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Oral Midazolam</measure>
    <time_frame>Pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h pd on D2 and 18, and 22 h pd on D3 and D19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (V/F) for Oral Midazolam</measure>
    <time_frame>Pre-dose (-0.5 h) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D2 and D18, and 22 h pd on D3 and D19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve from Time Zero to Time Tau, Where Tau is the Dosing Interval (AUC0-tau) for RO5186582 and RO5271857 (metabolite of RO5186582)</measure>
    <time_frame>D18: Pre-dose -0.17 h (10 min) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h pd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for RO5186582 and RO5271857 (metabolite of RO5186582)</measure>
    <time_frame>Pre-dose (10 min) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h pd on D18 (timepoints relative to oral midazolam dosing are (- 2 h 10 min), -1.5, -1, -0.5, 0 h pre-dose and 1, 2, 3, 4, 6, 8, and 10 h pd)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for RO5186582 and RO5271857 (metabolite of RO5186582)</measure>
    <time_frame>Pre-dose (10 min) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h pd on D18 (timepoints relative to oral midazolam dosing are (- 2 h 10 min), -1.5, -1, -0.5, 0 h pre-dose and 1, 2, 3, 4, 6, 8, and 10 h pd)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Ratio Based on AUC0-inf for IV Midazolam</measure>
    <time_frame>Pre-dose (-10 min) and 0.08 (5 min), 0.25 (15 min), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and D17, and 22 h pd on D2 and D18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Event-Related Potential (ERP) parameters Using Oddball Auditory</measure>
    <time_frame>D-1 (Baseline) and D16 at 1 and 4 h pd, time-matched to planned time, and D2 and D8 at 1 and 4 h pd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Electroencephalogram (EEG) Parameters</measure>
    <time_frame>D-1 (Baseline) and D16 at 1 and 4 h pd, time-matched to planned time, and D2 and D8 at 1 and 4 h pd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saccadic Eye Movement (SEM) Parameters</measure>
    <time_frame>D-1 (Baseline) and D16 at 1 h pd, time-matched to planned time, and D2 and D18 at 1 h pd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Attention and Memory of Selected Domains of Repeatable Battery for the Assessment of Neuropyschological Status (RBANSTM)</measure>
    <time_frame>D-1 (Baseline) and D16 at 2 and 5 h pd, time-matched to planned time, and D2 and D18 at 2 and 5 h pd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Concentration of 4 Beta-Hydroxy Cholesterol</measure>
    <time_frame>D1 (Baseline) and D17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve from Zero to Infinity (AUC0-inf) for Oral and IV Midazolam</measure>
    <time_frame>Midazolam (MDZ)-oral: pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h pd on D2 and 18, and 22 h pd on D3 and 19; MDZ-IV: Pre-dose (-10 min) and 5, 15 min, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and 17, and 22 h pd on D2 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for IV Midazolam</measure>
    <time_frame>Pre-dose (-10 min) and 5, 15 min, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and 17, and 22 h pd on D2 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve from Zero to Last Measurable Concentration (AUC[0-last]) for Oral and IV Midazolam</measure>
    <time_frame>MDZ-oral: pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h pd on D2 and 18, and 22 h pd on D3 and 19; MDZ-IV: Pre-dose (-10 min) and 5, 15 min, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and 17, and 22 h pd on D2 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) for Oral and IV Midazolam</measure>
    <time_frame>MDZ-oral: pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h pd on D2 and 18, and 22 h pd on D3 and 19; MDZ-IV: Pre-dose (-10 min) and 5, 15 min, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and 17, and 22 h pd on D2 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) for Oral and IV Midazolam</measure>
    <time_frame>MDZ-oral: pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 14 h pd on D2 and 18, and 22 h pd on D3 and 19; MDZ-IV: Pre-dose (-10 min) and 5, 15 min, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D1 and 17, and 22 h pd on D2 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearence (CL/F) for Oral Midazolam</measure>
    <time_frame>Pre-dose (-0.5 h) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 h pd on D2 and D18, and 22 h pd on D3 and D19</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>IV Midazolam Alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single 1 milligram (mg) dose of IV Midazolam on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Midazolam Alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single 5 mg oral dose of midazolam on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO5186582 Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO5186582 Plus IV Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO5186582 Plus Oral Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam, IV</intervention_name>
    <description>2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).</description>
    <arm_group_label>IV Midazolam Alone</arm_group_label>
    <arm_group_label>RO5186582 Plus IV Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam, oral</intervention_name>
    <description>0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.</description>
    <arm_group_label>Oral Midazolam Alone</arm_group_label>
    <arm_group_label>RO5186582 Plus Oral Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5186582</intervention_name>
    <description>RO5186582 120 mg film-coated release tablet.</description>
    <arm_group_label>RO5186582 Alone</arm_group_label>
    <arm_group_label>RO5186582 Plus IV Midazolam</arm_group_label>
    <arm_group_label>RO5186582 Plus Oral Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants with signed informed consent.

        Exclusion Criteria:

          -  A history of epilepsy, convulsions or significant head injury

          -  Significant history of drug allergy, as determined by the Investigator, or a known
             hypersensitivity to any of the ingredients of any of the study treatments

          -  Use of any drugs or substances, including herbal treatments such as St John's Wort,
             that are known to be substrates, inducers or inhibitors of CYP3A4 within 30 days of
             the first dose administration

          -  Pregnant or lactating

          -  Any other clinically relevant abnormalities, concomitant diseases or ongoing medical
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

